Background Emerging data suggest variability in susceptibility and outcome to coronavirus
disease 2019 (COVID-19) infection. Identifying risk factors associated with infection and …

Specific niches within the tumor bone marrow (BM) microenvironment afford a sanctuary for
multiple myeloma (MM) clones due to stromal cell-tumor cell interactions, which confer …

High‐dose melphalan and stem cell transplantation (HDM/SCT) is an effective treatment for
selected patients with AL amyloidosis. We report the long‐term outcomes of 648 patients …

Methods We used the national Veterans Affairs (VA) electronic health record to define a
retrospective cohort of patients with one or more SARS-CoV-2 microbiologic test results (…

Daratumumab as a single agent (sDARA) or in combination with chemotherapies (cDARA)
leads to impressive hematologic and organ responses in AL amyloidosis. However, …

Genomic instability (GIN), an increased tendency to acquire genomic alterations, is a cancer
hallmark. However, its frequency, underlying causes, and disease relevance vary across …

The relationship between promoter proximal transcription factor-associated gene expression
and super-enhancer-driven transcriptional programs are not well defined. However, their …

Multiple myeloma (MM) is a heterogeneous disease that has an increased incidence in African
Americans (AAs). We previously observed that, with equal access to health care, younger …

Light chain (AL) amyloidosis is an uncommon clinical manifestation of Waldenström
macroglobulinemia (WM), an IgM-secreting lymphoplasmacytic lymphoma characterized by …

Background: Liver involvement in light chain amyloidosis (AL) is seen in up to 20% of
patients and is typically encountered as part of multi-organ involvement. Liver involvement is …